Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - September 04, 2026 03:03 pm IST - HYDERABAD
Contract research, development and manufacturing organisation Cohance Lifesciences, formerly Suven Pharmaceuticals, is strengthening its antibody-drug conjugate (ADC) strategy with fresh investments in two biotechnology companies.
It is investing an additional $13 million in NJ Bio and making a controlling investment of $5 million in Aruka Bio, expanding its capabilities and presence in the growing ADC segment.
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships.
Both the transactions will be funded through internal accruals, Cohance said on Thursday (September 3, 2026).
The company will increase its common-equity ownership in NJ Bio from 56% to 67.3%, acquiring the entire holdings of Priyashri Nayak and the Jain Family Irrevocable Trust.
Dr.
Naresh Jain will retain the remaining 32.7% and continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives.
NJ Bio will remain focused on customer-facing contract research, development and manufacturing services.
Aruka is a biotechnology firm based in Princeton, New Jersey and focused on developing next-generation antibody-drug conjugates.
Its lead programme is currently at the preclinical stage.
Cohance’s $5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital.
On completion, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr.
Jain.
The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.
The decisions follows a review of NJ Bio’s performance and integration since the original investment in December 2024 when Cohance had acquired a 56% equity stake in a $64.4 million transaction.
business (general) / pharmaceutical / health / private health care / investments / foreign investment
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
